Jul 28, 2025
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Jun 23, 2025
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
May 26, 2025
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 15, 2025
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
May 05, 2025
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
Apr 29, 2025
Immutep Quarterly Activities Report Q3 FY25
Mar 24, 2025
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
Mar 19, 2025
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Jan 30, 2025
Immutep Quarterly Activities Report Q2 FY25
Jan 21, 2025
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Jan 06, 2025
Patient Enrolment Completed for INSIGHT-003
Dec 16, 2024
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
